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lncRNAs are known to regulate a number of different
developmental and tumorigenic processes. Here, we
report a role for lncRNA BCAR4 in breast cancer
metastasis that is mediated by chemokine-induced
binding of BCAR4 to two transcription factors with
extended regulatory consequences. BCAR4 binding
of SNIP1 and PNUTS in response to CCL21 releases
the SNIP1’s inhibition of p300-dependent histone
acetylation, which in turn enables the BCAR4-re-
cruited PNUTS to bind H3K18ac and relieve inhibition
of RNA Pol II via activation of the PP1 phosphatase.
This mechanism activates a noncanonical Hedge-
hog/GLI2 transcriptional program that promotes
cell migration. BCAR4 expression correlates with
advanced breast cancers, and therapeutic delivery
of locked nucleic acids (LNAs) targeting BCAR4
strongly suppresses breast cancer metastasis in
mouse models. The findings reveal a disease-rele-
vant lncRNAmechanism consisting of both direct co-
ordinated protein recruitment and indirect regulation
of transcription factors.
INTRODUCTION
Emerging evidence has purported long noncoding RNA (lncRNA)
as a new class of players involved in the development and pro-
gression of cancer (Fatica and Bozzoni, 2014). However, the reg-
ulatory roles played by lncRNAs in breast-cancer-associated
aberrant signaling pathways/transcriptional programs are not
completely understood. lncRNAs exert their regulatory functions
through specific interactions with proteins, including via epige-
netic modifiers, transcriptional factors/coactivators, and RNP
complexes (Rinn and Chang, 2012). The specific lncRNA-protein
interactions could be mediated by canonical RNA-binding
domains (RBDs) (Lunde et al., 2007) or by noncanonical1110 Cell 159, 1110–1125, November 20, 2014 ª2014 Elsevier Inc.RBDs, including tryptophan-aspartic acid 40 (WD40) domain
and RNA-binding domain abundant in Apicomplexans (RAP),
demonstrated by recent mRNA interactome capture methodol-
ogy (Castello et al., 2012). Therefore, it is of great interest to un-
cover new functions of lncRNAs by dissecting lncRNA-protein
interactions mediated by noncanonical RBDs in certain biolog-
ical processes.
The aberrant activation of the hedgehog signaling pathway in
breast cancer has been connected with increased expression of
the transcription factor, glioma-associated oncogene homolog
1/2 (GLI1/2) (ten Haaf et al., 2009). GLI1/2-dependent target
gene transcription has been shown to be involved in tumor cell
growth and metastasis in solid tumors (Rubin and de Sauvage,
2006). However, GLI-target transcription might be activated
in the absence of the hedgehog ligand sonic hedgehog (SHH),
especially in triple-negative breast cancer (TNBC) (Hui et al.,
2013), suggesting that other mechanisms/regulators may regu-
late the activity of the GLI transcription factor. The direct binding
of lncRNAs to transcription factors (Geisler and Coller, 2013)
led us to speculate that the association of transcription factor
GLI with lncRNAs may function in regulating GLI-dependent
transcriptional program essential for breast cancer progression
and metastasis.
The lncRNAs implicated in breast cancer represent a prom-
ising class of therapeutic targets. Targeting noncoding RNAs
by using locked nucleic acid (LNA)-based antisense oligonucle-
otides strategy has been a longstanding interest (Dias and Stein,
2002), with several successful applications in targeting miRNAs
in cancer (Ling et al., 2013). However, therapeutic targeting
of lncRNA has not been well documented for breast cancer.
Thus, we aimed to determine the therapeutic potential of target-
ing breast cancer-upregulated lncRNAs by a LNA-based anti-
sense oligonucleotides strategy.
Here, we report the identification of a signaling pathway that is
triggered by CCL21 and mediated by citron (rho-interacting,
serine/threonine kinase 21) (CIT) kinase to phosphorylate
the transcriptional factor GLI2, which regulates target gene
expression in breast cancer cells. The lncRNABCAR4 is required
for phospho-GLI2-dependent gene activation via its direct
interaction with Smad nuclear-interacting protein 1 (SNIP1)
and Serine/threonine-protein phosphatase 1 regulatory subunit
10 (PPP1R10, also known as PNUTS). Mechanistically, the
BCAR4-SNIP1 binding releases the inhibitory role of SNIP1 on
p300 histone acetyltransferase (HAT) activity, leading to the
acetylation of histones, including a novel mark, H3K18ac, on
the promoters of GLI2 target transcription units. The acetylated
H3K18 can be further recognized by PNUTS, which is recruited
to the promoters of GLI2 target genes by BCAR4, to attenuate
the protein’s inhibitory effect on the enzymatic activity of PP1,
leading to hypophosphorylation of RNA polymerase II at Ser5.
Elevated BCAR4 expression is correlated with higher metastatic
potential and shorter survival time of breast cancer patients,
whereas its therapeutic inhibition by LNA displays in vivo efficacy
against metastasis. Our findings have provided supporting evi-
dence for the regulatory roles played by lncRNAs in the progres-
sion of aggressive breast cancers. Broadly, our results of the
therapeutic effectiveness of BCAR4 LNA against breast cancer
metastasis document an example showing the pharmacologic
value of lncRNA in human cancer and other diseases.
RESULTS
BCAR4 Correlates with Advanced Breast Cancer and
Regulates GLI-Mediated Transcription
To identify breast cancer-relevant lncRNAs, we profiled the
expression of lncRNAs in two stage III breast cancer tissues
and their paired adjacent noncancerous tissues (Figure S1A
available online) by LncRNA Array (v. 3.0) (ArrayStar). An average
of 1,381 upregulated lncRNAs (range from 1,034 to 1,729) and
1,458 downregulated lncRNAs (range 1,408–1,508) with signifi-
cantly differential expression (R3.0-fold) were identified (Fig-
ure 1A; Table S1). We further compared the lncRNA expression
levels between breast cancer tissues and their paired adjacent
normal tissues based on the NCBI RefSeq database (which
contains 3,991 human lncRNAs with annotated NR accession
number), identifying 65 and 116 upregulated lncRNAs in two
patient cases, respectively (R4.0-fold) (Figure 1B). Among
these lncRNAs, 21 were consistently upregulated in both patient
samples, of which BCAR4, initially identified through genetic
screening as a novel gene involved in tamoxifen resistance in
breast cancers (Meijer et al., 2006), showed the most upregula-
tion (logFC: 15.9 and 16.1, respectively) (Figures S1B and S1C).
We first performed RNA in situ hybridization on breast cancer
tissue microarrays (clinicopathological features listed in Table
S2) using RNAScope 2.0 HD technology to examine the potential
correlation of BCAR4 with breast cancer. In a training set of
breast cancer tissue microarrays containing 232 cases,
BCAR4 exhibited positive staining only in 10% of the normal
breast tissues, whereas 54.10% of breast cancer tissues
showed positive BCAR4 expression (p = 0.0057) (Figure 1C). In
a validation set containing 170 cases, none of ten normal adja-
cent breast tissues showed detectable BCAR4 expression, but
61.88%of breast cancer tissues exhibited positiveBCAR4 stain-
ing (p = 0.0011) (Figure 1C). Furthermore, breast cancer at
advanced lymph nodemetastasis stage (TnN > 0MR 0) showed
increased BCAR4 expression compared to those at early-stage
tumor with no lymph node metastasis (TnN0M0) (p = 0.0001,Ctraining set; p = 0.0035, validation set) (Figure 1D). Elevated
BCAR4 expression also significantly correlates with shorter
survival time of breast cancer patients (n = 160; p = 0.0145)
(Figure 1E). We further analyzed breast cancer database in
Oncomine, finding that BCAR4 expression not only correlates
with breast cancer but also with triple negativity lymph node
metastasis and 5 years recurrence (Figure S1D). Oncomine
database also showed significant correlation of BCAR4 expres-
sion with metastatic prostate cancer, lung cancer, colorectal
cancer, and rectal cancer (Figure S1D). To confirm this, we em-
ployed the RNAScope Assay to analyze BCAR4 expression in
normal and cancer tissues from multiple organ, observing
increased BCAR4 expression in many types of human cancer
tissues, including colorectal, melanoma, and lung cancer,
compared to normal tissues (Figure 1F; Table S3). Taken
together, these results demonstrated the strong correlation of
BCAR4 expression with breast cancer progression and the rele-
vance of elevated BCAR4 expression to human cancer develop-
ment and progression.
We then examined the expression of BCAR4 in a panel of
breast cancer cell lines, finding higher expression of BCAR4 in
mesenchymal-like cell lines with metastasis potential compared
to epithelial-like cell lines, which are considered as nonmeta-
static (Figure 1G). Next, we examined the subcellular localization
of BCAR4 by RNA fluorescence in situ hybridization (FISH) and
qRT-PCR analyses on fractionated RNA, finding that the
BCAR4 transcript is predominately localized in the nucleus (Fig-
ures 1H and S1E). BCAR4 has two major splice variants, full-
length transcript (1.3 kb) and an isoform lacking two alternate
exons (680 bp), and our northern blot analysis revealed that
the full-length isoform was predominately expressed in MDA-
MB-231 cells, but truncated isoform barely expressed (Fig-
ure S1F). Because the previous report suggested that BCAR4
may encode a small peptide in bovine oocytes (The´lie et al.,
2007), we generated an antibody using the predicted translated
peptide sequence. However, neither immunoblotting of MDA-
MB-231 lysate nor in vitro translation assays showed protein
coding potential of BCAR4 (Figure S1G; data not shown).
We next analyzed the effect of BCAR4 knockdown on activa-
tion of key signaling pathways in breast cancer cells using the
Cignal Finder 45-Pathway Reporter Array, finding that either
small interfering RNA (siRNA) or LNA efficiently depleted
BCAR4 expression (Figures S1H and S1I) and knockdown of
BCAR4 dramatically inhibited GLI reporter luciferase activity
but no other transcription factor reporters (Figure 1I). qRT-PCR
analysis confirmed decreased expression of endogenous GLI
target genes with BCAR4 knockdown (Figure 1J). These data
suggest the potential role ofBCAR4 in mediating the GLI-depen-
dent hedgehog signaling pathway in breast cancer cells.
Identification and Biochemical Characterization of
BCAR4-Associated Proteins
Through RNA pull-down, followed by mass spectrometry (MS)
analysis, we identified that in vitro-transcribed biotinylated
BCAR4 sense transcript associated specifically with CIT kinase,
GLI2, SNIP1, and PNUTS, even under high stringency wash con-
ditions. However, the antisense transcript of BCAR4 associated
with some general RNA-binding proteins that were also boundell 159, 1110–1125, November 20, 2014 ª2014 Elsevier Inc. 1111
Figure 1. BCAR4 Correlates with Breast Cancer Metastasis
(A) Scatter plots of lncRNAs significantly upregulated (red) or downregulated (green) in two pairs of TNBC tissues compared to the matched adjacent normal
tissues (NBT). x and y axes, averaged normalized signal values (log2 scaled); green lines, fold changes = 4.
(B) Commonly upregulated lncRNAs in two pairs of TNBC compared to NBT.
(C) RNAScope detection of BCAR4 expression in human breast cancer and adjacent normal tissues. Left panel: representative images; right panel: statistical
analysis of training set (10 normal tissues versus 222 cancer tissues) and validation set (10 normal tissues versus 160 cancer tissues).
(D) RNAScope detection of BCAR4 expression in nonmetastasis (TnN0M0) versus metastasis (TnN > 0MR 0) breast cancer tissue. Left panel: representative
images; right panel: statistical analysis of training set (167 nonmetastasis versus 55 Metastasis) and validation set (66 nonmetastasis versus 94 metastasis).
(E) Kaplan-Meier survival analysis of BCAR4 expression in breast cancer patients (n = 160).
(F) RNAscope detection of BCAR4 expression in multiple human tissues.
(legend continued on next page)
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by the beads (Figures 2A and S2A; Table S4). Of note, in one of
two biological repeats of RNA pull-down experiment, we
observed the relative abundant association of BCAR4 with
heterogeneous nuclear ribonuclearprotein, which have been re-
ported to bind other lncRNAs (Carpenter et al., 2013; Huarte
et al., 2010). Furthermore, the MS data indicated the potential
phosphorylation of GLI2 at Serine149 (Figure S2B).
The RNA pull-down assays with cell lysate further confirmed
the specific association of BCAR4 with the proteins identified
by MS analysis (Figure 2B). In vitro RNA-protein binding assay
revealed that only PNUTS and SNIP1 directly interact with
BCAR4 (Figures 2C and S2C). Protein domain mapping studies
demonstrated that BCAR4 binds the 97–274 amino acid (aa) re-
gion of SNIP1 and 674–750 aa region of PNUTS, respectively
(Figures 2D and 2E). The 97–274 aa region of SNIP1 encodes a
domain known as the domain of unknown function (DUF) and
has been suggested to bind miRNA (Yu et al., 2008), an observa-
tion that is consistent with our observation that the DUF of SNIP1
serves as the RNA-binding domain for BCAR4. PNUTS also has
an RNA-binding motif, the 674–750 aa region known as RGG-
box (Kim et al., 2003). To further understand the BCAR4-protein
interactions in vivo, we performed immunoprecipitation using
antibodies against CIT, GLI2, SNIP1, and PNUTS, respectively,
under the condition of BCAR4 knockdown (Figures S2D and
S2E), finding that knockdown of BCAR4 impaired the interaction
of PNUTS with proteins CIT, GLI2, and SNIP1, but had minimal
effect on the association of CIT, GLI2, and SNIP1 with each other
(Figure S2E). Given the observation that only SNIP1 and PNUTS
directly bound to BCAR4 (see Figure 2C), our data suggest that
SNIP1 mediates the association of CIT and GLI2 with BCAR4
and that SNIP1 and PNUTS bind distinct regions of BCAR4.
To map the BCAR4 sequence motifs responsible for SNIP1
and PNUTS binding, we performed an in vitro RNA pull-
down followed by dot blot assay (Yang et al., 2013). The
motif sequence of BCAR4 bound/protected by SNIP1 and
PNUTS was identified to encompass 235TGT.GGA288 and
991GTT.ATA1044, respectively (Figure 2F). However, the gluta-
thione S-transferase (GST) protein showed no specific binding
to any region of BCAR4 (Figure 2F). Deletion of the correspond-
ing sequence of BCAR4 (D212–D311) abolished its interaction
between SNIP1 with no effect on PNUTS binding (Figure 2G).
Deletion of the motif sequence D968–D1087 of BCAR4 abol-
ished its interaction with PNUTS, but not with SNIP1 (Figure 2G).
Electrophoretic mobility shift assays (EMSAs) were further used
to confirm the direct binding of BCAR4 with SNIP1 and PNUTS.
Incubation of the BCAR4 RNA probe (nucleotide [nt] 235–288)
and (nt 991–1044) with recombinant SNIP1 and PNUTS, respec-
tively, resulted in specific gel retardation (Figure 2H). Under
these conditions, no shift was observed when the correspond-
ing cold probes were used (Figure 2H). We, therefore, conclude
that BCAR4 directly bind to SNIP1 and PNUTS via two distinct
regions.(G) qRT-PCR detection of BCAR4 expression in a panel of cell lines.
(H) Nuclear localization of BCAR4 detected by RNA FISH in MDA-MB-231 cells.
(I) Identification of signal pathways affected by BCAR4 knockdown in MDA-MB-
(J) qRT-PCR detection of GLI-target genes expression. Error bars, SEM of three
See also Figure S1 and Tables S1, S2, and S3.
CGivenMS data showing that GLI2 is phosphorylated at Ser149
and associates with CIT kinase (see Figures 2A and S2B), we
reasoned that CIT may serve as a kinase to phosphorylate
GLI2. An in vitro kinase assay indicated that bacterially ex-
pressed wild-type (WT) GLI2 was phosphorylated by CIT, but
not S149Amutant (Figure S2F). ULK3 served as the positive con-
trol due to its reported ability to phosphorylate GLI (Maloverjan
et al., 2010). An in vitro RNA-protein binding assay using bio-
tinylated BCAR4 and GLI2 proteins phosphorylated by CIT
in vitro showed no interaction (Figure S2G).
To investigate the role of GLI2 Ser149 phosphorylation in vivo,
we generated rabbit polyclonal antibodies that specifically
recognized Ser149-phosphorylated GLI2 referred to as p-GLI2
(Ser149) antibody,which specifically detectedbacterially purified
GLI2 protein that phosphorylated by CIT in vitro, with minimal
reactivity toward GLI2 phosphorylated by ULK3 (Figure 2I). We
conclude that p-GLI2 (Ser149) antibody specifically recognizes
CIT-mediated Ser149 phosphorylation of GLI2. Next, we eval-
uate the level of phospho-GLI2 in breast cancer by immunohisto-
chemistry (IHC) analysis of clinical tumor specimens, finding
higher p-GLI2 (Ser149) levels in invasive breast cancer tissues
compared with adjacent normal tissues (p = 0.0087) (Figure 2J).
Our IHC staining further revealed increased p-GLI2 (Ser149) level
inmultiple cancer types compared to their corresponding normal
tissues (Figure S2H; Table S5). IHC analysis also revealed higher
CIT expression in invasive breast cancer comparedwith adjacent
normal breast tissues (p = 0.0055) (Figure S2I) and the staining of
phosphorylated GLI2 strongly correlated with that of BCAR4 and
CIT staining (data not shown). Taken together, we identified and
characterized that BCAR4 binds a protein complex containing
SNIP1, PNUTS, phosphorylated GLI2, and CIT via its direct inter-
action with SNIP1 and PNUTS.
CCL21 Induces GLI2 Ser149 Phosphorylation and
Nuclear Translocation of Phosphorylated GLI2
The CIT kinase-mediated GLI2 phosphorylation prompted us
to investigate whether this phosphorylation could be triggered
in MDA-MB-231 cells by hedgehog signaling. Surprisingly,
although the ligand SHH activated hedgehog signaling in Daoy
cells evidenced by stimulated SHH gene induction as previously
reported (Wang et al., 2012), minimal effect was observed in
MDA-MB-231 cells (Figure S3A), and no phosphorylated GLI2
was detected (data not shown), suggesting that a noncanonical
hedgehog signaling pathway, involving Ser149-phosphorylated
GLI2, may exist in breast cancer.
We then explored whether extracellular signals that activate
CIT kinase could also trigger GLI2 phosphorylation in breast can-
cer cells. Given that CIT kinase can be activated by GTPase Rho
proteins (Madaule et al., 1998), we first screened the CIT-Rho
interaction in breast cancer cells. Although CIT kinase is consti-
tutively associated with RhoA as previously reported (Gai et al.,
2011), the presence of Rho activator specifically triggered the231 cells. x and y axes, normalized ratio of firefly/Renilla luciferase activities.
independent experiments (*p < 0.05, **p < 0.01, and ***p < 0.001).
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Figure 2. Identification and Biochemical Characterization of BCAR4-Associated Proteins
(A) A list of top BCAR4-associated proteins identified by RNA pull-down and MS analysis in MDA-MB-231 cells: R1 and R2 (biological repeat 1 and 2).
(B andC) Immunoblot (IB) detection of proteins retrieved by in vitro-transcribed biotinylatedBCAR4 fromMDA-MB-231 cell lysates (B) and indicated recombinant
proteins (C).
(legend continued on next page)
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interaction between RhoC and CIT kinase (Figure S3B). Then we
hypothesized that the RhoC-activating stimulus may activate
CIT kinase. Indeed, we screened 13 known growth factors/cyto-
kines/chemokine involved in RhoC activation and breast cancer
metastasis (Favoni and de Cupis, 2000; Kakinuma and Hwang,
2006), finding that CXCL12, CCL21, IGF-I, PDGF-BB, and
TGF-b1 enhanced the interaction between RhoC and CIT (Fig-
ure 3A). The same stimuli induced activation of CIT kinase indi-
cated by phosphorylation of MLC, a classic CIT kinase substrate
(Yamashiro et al., 2003), with CCL21 exhibiting the highest in-
duction (Figure S3C). We then tested the phosphorylation of
GLI2 in MDA-MB-231 cells treated with CXCL12, CCL21, IGF-
1, PDGF-BB, and TGF-b1, finding that CCL21 dramatically
induced Ser149 phosphorylation of GLI2 (Figure 3B), which
was significantly reduced by CIT knockdown (Figure 3C).
Consistently with previous finding that CCL21-CCR7 autocrine
signaling is critical for breast cancer metastasis (Mu¨ller et al.,
2001), treatment of MDA-MB-231 cells with either neutralizing
anti-CCL21 or anti-CCR7 antibodies inhibited basal or CCL21-
induced GLI2 phosphorylation (Figures S3D and S3E). CCL21
treatment also dramatically induced GLI2 Ser149 phosphoryla-
tion in a panel of additional cancer cell lines, ruling out the pos-
sibility of cell line-specific effect (Figure S3F).
Next, we investigated the functional consequence of Ser149
phosphorylation on GLI2. In the cytoplasm, GLI is associated
with the suppressor of fused homolog (SUFU), which regulates
the cellular localization of GLI (Dunaeva et al., 2003). We
performed coimmunoprecipitation experiments and observed
that CCL21 treatment induced dissociation between GLI2 and
SUFU (Figure S3G), whereas the exogenously expressed GLI2
S149A mutant failed to release from SUFU in response to
CCL21 (Figure 3D). Given that SNIP1, which is in the same com-
plex with GLI2 (see Figure 2A), harbors an FHA domain that rec-
ognizes phosphoserine/threonine, we hypothesized that Ser149
phosphorylation of GLI2 is required for its interaction with SNIP1
via the FHA domain. Indeed, either knockdown of CIT or intro-
duction of S149A mutant reduced CCL21-induced interaction
between GLI2 and SNIP1 (Figures 3C and 3E). Consistently,
deletion or point mutation of amino acids that are critical for
FHA domain function (Durocher et al., 2000) also abolished
SNIP1’s interaction with phosphorylated GLI2 (Figures 3F and
3G). We then performed nuclear fractionation experiments,
finding that phosphorylated GLI2 translocated to the nucleus
upon CCL21 treatment; whereas CIT, SNIP1, and PNUTS did
not exhibit relocation (Figure 3H). The phospho-GLI2-specific
antibody also exhibited nuclear staining patterns in breast
cancer tissue samples (see Figure 2J). Knockdown of CIT or(D and E) IB detection of Myc-tagged SNIP1 (D) and PNUTS (E) (WT versus dom
Lower panels: graphic illustration of the domain structure of SNIP1 (D) or PNUTS
(F) In vitro RNA-protein binding, followed by dot blot assays. Bottom panel: schem
PNUTS, respectively.
(G) IB detection of proteins retrieved by in vitro-transcribed biotinylated BCAR4
(H) EMSA of recombinant SNIP1 and PNUTS binding to BCAR4 nt 235–288 and
(I) In vitro kinase assay showing CIT-mediated phosphorylation of GLI2 (WT vers
(J) IHC staining of phospho-GLI2 (S149) in human breast cancer and adjacent no
normal tissues versus 222 cancer tissues is shown.
See also Figure S2 and Tables S2, S4, and S5.
CSNIP1 abolished CCL21-induced nuclear translocation of GLI2
(Figure 3I). In accordance with this, GLI2 S149A mutant failed
to translocate into the nucleus upon CCL21 treatment (Fig-
ure S3H). Our findings reveal a CCL21/CIT kinase/phospho-
GLI2/SNIP1 signaling cascade in breast cancer cells, which
may represent a noncanonical hedgehog pathway.
BCAR4 Is Required for Transcription Activation of
Phospho-GLI2-Dependent Target Genes in Breast
Cancer Cells
To test if CCL21/CIT/SNIP1 signaling axis-mediated phospho-
GLI2 nuclear translocation leads to the activation of GLI target
genes, we performed a chromatin immunoprecipitation (ChIP)
assay using antibodies against GLI2 or phospho-GLI2, finding
that Ser149 phosphorylated GLI2 was present on the promoters
of several well-established GLI target genes PTCH1, IL-6,
MUC5AC, and TGF-b1, but not on the promoter of a non-GLI
target gene, RPLP0 (Figures 4A and 4B). We then performed
a chromatin isolation by RNA purification (ChIRP) assay to
examine the genomic occupancy of BCAR4, finding that in
response to CCL21 treatment, BCAR4 was recruited to the
promoters of PTCH1, IL-6, MUC5AC, and TGF-b1 (Figures 4C,
S3I, and S3J). Consistently, either knockdown of BCAR4 or
overexpression of GLI2 S149A mutant dramatically impaired
CCL21-induced expression of PTCH1, IL-6, MUC5AC, and
TGF-b1 genes (Figure 4D; data not shown).
One of themajor biological roles of GLI is tomodulate the gene
expression related to cell migration and invasion (Feldmann
et al., 2007). Thus, we examined the effect of GLI2, BCAR4,
and other BCAR4 bound proteins on breast cancer cell invasion
and migration. The treatment of MDA-MB-231 cells with vali-
dated siRNAs against BCAR4, CIT, SNIP1, or PNUTS or neutral-
izing antibody against CCL21 all dramatically inhibited cell
migration (Figures 4E–4G) and invasion (Figure 4H; data not
shown) but did not affect cell proliferation (Figure S4A). Consis-
tently, stable knockdown of BCAR4 by small hairpin RNAs
(shRNAs) in MDA-MB-231 LM2 cells reduced migration and in-
vasion properties of these cells (Figures S4B–S4D). We also
tested if BCAR4 is critical for migration and invasion of those
metastatic cancer cell lines that respond to CCL21 treatment
(see Figure S3F). Our data showed that while knockdown of
BCAR4 had no effect on proliferation of HCT116, H1299,
HepG2, and Hey8 cells (Figures S4E and S4F), the migration
and invasion of these cells were significantly reduced (Figures
S4G and S4H; data not shown). In addition, CCL21-induced
GLI2 target genes expression in these cell lines was inhibited
by BCAR4 knockdown (Figures S4I and S4J; data not shown).ain truncation mutants) retrieved by in vitro-transcribed biotinylated BCAR4.
(E).
atic illustration of the BCAR4 sequence motifs that is recognized by SNIP1 and
(WT versus D212–D311 and D968–D1087) from MDA-MB-231 cell lysates.
nt 991–1044, respectively.
us S149A). *, unspecific band.
rmal tissues. Left: representative image. Right: statistics analysis based on 10
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Figure 3. Identification of a Noncanonical Hedgehog Signaling Pathway Mediated by CCL21/CIT/Phospho-GLI2 Signaling Axis
(A and B) Immunoprecipitation (IP) and IB detection of CIT-RhoC interactions (A) and GLI2 phosphorylations (B) in cells treated with indicated growth factors,
cytokines, or chemokines.
(C) IP and IB of GLI2 phosphorylations in cells transfected with indicated siRNAs followed by CCL21 treatment.
(D and E) IP and IB detection of GLI2-SUFU (D) or GLI2-SNIP1 (E) interactions in MDA-MB-231 cells transfected with GLI2 (WT versus S149A) followed by CCL21
treatment.
(legend continued on next page)
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Given that BCAR4 is critical for metastasis potential of cancer
cells and our observation of lower BCAR4 expression level in
nonmetastatic breast cancer cell lines compared to metastatic
breast cell lines (see Figure 1G), we reasoned that overexpres-
sion of BCAR4 in a nonmetastatic cell line may increase its
metastasis potential. MCF-7 is a nonmetastatic breast cancer
cell line but expresses the CCR7, the receptor for CCL21 (Mu¨ller
et al., 2001). Indeed, stimulation of MCF-7 cells with CCL21
modestly enhanced their invasion (Figure 4I). However, overex-
pression of full-length BCAR4, but not the deletion mutants
abolishing SNIP1 or PNUTS binding in MCF-7 cells (Figure S4K),
increased the invasion and GLI2 target genes expression
even under the basal condition (Figures 4I, 4J, and S4L), which
was not due to cell proliferation effect (Figure S4M). These
data strongly argue the important role of BCAR4 in the phos-
pho-GLI2-mediated transcription activation of a subset of genes,
which may contribute to breast cancer cell migration and
invasion.
BCAR4 Binds SNIP1 and Releases the Inhibitory Effect
of SNIP1 on p300 HAT Activity
Next, we investigated the molecular mechanism by which
BCAR4 regulates GLI2 target genes expression. Considering
that BCAR4 directly interacts with SNIP1 in vitro, we explored
whether this interaction is functionally important in vivo by exam-
ining the SNIP1-BCAR4 interaction by an RNA immunoprecipita-
tion (RIP) assay, finding that in response to CCL21 treatment,
SNIP1 bound to BCAR4 in multiple cancer cell lines (Figures
S5A–S5C). As a control, no interaction between SNIP1 and
NEAT2, an abundant nuclear lncRNA, was observed (Figures
S5A–S5C). As expected, deletion of the 97–274 aa region abol-
ished SNIP1-BCAR4 interaction (Figure 5A), which is consistent
with our previous observation that the DUF domain of SNIP1 is
required for SNIP1-BCAR4 interaction (see Figure 2D). Surpris-
ingly, deletion of the FHA domain (region 274–349 aa) of SNIP1
led to constitutive SNIP1-BCAR4 interaction (Figures 5A and
S5D), suggesting that binding to phosphoserine/threonine via
its FHA domain, is required for SNIP1’s subsequent interaction
with BCAR4, possibly through a mechanism involving the
conformational change of SNIP1 upon phospho-GLI2 binding.
Indeed, FHA domain mutants of SNIP1 all failed to interact with
BCAR4, whereas wild-type SNIP1 along with the D356Nmutant,
which exhibits no effect on phospho-GLI2 binding, was able to
bind BCAR4 (Figure 5B). These data suggest that SNIP1’s FHA
domain may block the DUF domain, preventing SNIP1-BCAR4
interaction. Upon stimulation, the FHA domain recognizes phos-
pho-Ser149 of GLI2, which causes conformational changes that
may expose the DUF domain for BCAR4 binding.
SNIP1 has been reported to interact with p300 and potentially
regulates p300-dependent gene transcription (Kim et al., 2000).
Although immunoprecipitation of SNIP1 confirmed its interaction
with p300, the interaction was not affected by deprivation of(F and G) IP and IB detection of GLI2-SNIP1 interactions in cells transfected with S
followed by CCL21 treatment.
(H and I) IP and IB (H) and Immunofluorescence (I) detection of phospho-GLI2 nuc
(H) or transfected with indicated siRNAs followed by CCL21 treatment (I).
See also Figure S3.
CBCAR4 (Figure S5E). Deletion of either DUF domain of SNIP1 (re-
gion 97–274 aa) or the BCAR4 SNIP1 binding motif (nt 212–311)
exhibited minimal effect on SNIP1-p300 interaction (Figures S5F
and S5G). We then examined the HAT activity of p300 in the
presence of SNIP1 and/or BCAR4. Surprisingly, the HAT activity
of p300, was strongly inhibited by recombinant SNIP1 but could
be rescued by in vitro-transcribed BCAR4 RNA (Figure 5C). This
rescue was dependent on the interaction between BCAR4 and
SNIP1’s DUF domain because the presence of BCAR4 alone
had no effect on the HAT activity of p300. Moreover, deletion
of BCAR4’s SNIP1 binding motif (nt 212–311) abolished the
rescue of p300’s HAT activity (Figure 5C). Therefore, our data
indicated that the interaction between SNIP1 and BCAR4
released the inhibitory role of SNIP1 on the HAT activity of p300.
Although it has been suggested that SNIP1 regulates the
p300-dependent transcription of multiple signaling pathways
(Fujii et al., 2006; Kim et al., 2000, 2001), the mechanism is
not clear. We mapped the domains of SNIP1 that may interact
with p300 and found that while both the N-terminal (2–80 aa)
and DUF domain (97–274 aa) of SNIP1 were required for
p300 binding (Figure S5H), the DUF domain of SNIP1 is the
minimum region required to inhibit the enzymatic activity
of p300 (Figure 5D). By incubating SNIP1 with p300 catalytic
unit (aa 1198–1806) and derivative truncation mutants, we
found that the DUF domain of SNIP1 interact with PHD (aa
1198–1278) and CH3 domains (aa 1664–1806) of p300 catalytic
unit, which may interfere with p300’s HAT activity (Figure 5E).
According to our in vitro observations, the DUF domain also
binds BCAR4, raising a possible role of BCAR4 in regulating
p300’s HAT activity. Indeed, in the presence of BSA and
tRNA, p300 exhibited dose-dependent HAT activity, which
was abolished in the presence of SNIP1 DUF domain alone
(Figure 5F). In contrast, in the presence of sense but not anti-
sense BCAR4, p300 HAT activity was largely rescued (Fig-
ure 5F). These data suggest that the DUF domain of SNIP1
binds PHD and CH3 domains of p300 to inhibit the HAT
activity, whereas signal-induced binding of BCAR4 to SNIP1
DUF domain releases its interaction with the catalytic domain
of p300, leading to the activation of p300.
p300-mediated histone acetylation is critical for transcription
activation (Wang et al., 2008). We then screened histone acety-
lation on GLI2 target gene promoters, finding that H3K18ac,
H3K27ac, H3K56ac, H4K8ac, H4K12ac, and H4K16ac
were induced by CCL21 treatment in breast cancer cells, with
H3K18ac showing the highest level (Figure 5G). Knockdown of
BCAR4 abolished CCL21-induced H3K18 acetylation on GLI2
target gene promoters; however, this was not due to reduced
recruitment of phosphorylated-GLI2 or p300 to GLI2 (Figure 5H).
These findings suggest that BCAR4 activates p300 by binding
SNIP1’s DUF domain to release the inhibitory effect of SNIP1
on p300, which results in the acetylation of histone marks
required for gene activation.NIP1 (WT versus D274–D349) (F) or (WT versus FHA domain point mutants) (G)
lear translocation in cells treated with CCL21 treatment at different time points
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Recognition of BCAR4-Dependent Histone Acetylation
by PNUTS Attenuates Its Inhibitory Effect on PP1
Activity
Based on our data that the 30 of BCAR4 interacts with PNUTS
in vitro, we next examined this interaction in vivo by RIP experi-
ments. We found that PNUTS constitutively interacts with
BCAR4 via its RGG domain (Figures 6A, S5A–S5C, and S6A),
an observation that is consistent with our in vitro data (see Fig-
ure 2E). PNUTS functions as a regulatory subunit for PP1, inhib-
iting the phosphatase activity of PP1 (Kim et al., 2003). As such,
we wondered whether BCAR4 could regulate PP1’s phospha-
tase activity via binding PNUTS. The immunoprecipitation assay
indicated that knockdown of BCAR4 has minimal effect on
PNUTS-PP1A interaction (Figures S1I and S6B). As previously
reported (Kim et al., 2003), the phosphatase activity of PP1
was inhibited by PNUTS (Figure S6C). However, neither sense
nor antisense BCAR4 could rescue PP1’s activity (Figure S6D),
leading us to explore whether any histone modifications could
rescue PP1 activity given that recruitment of the PNUTS/PP1
complex by BCAR4 could possibly activate the transcription of
GLI2 target genes.
Surprisingly, the inhibition of PP1’s phosphatase activity by
PNUTS was largely rescued by purified nucleosome from HeLa
cells but not by recombinant nucleosome, whereas neither
nucleosome alone affected PP1 activity (Figure 6B), suggesting
that modified histones binding is critical to release PNUTS’s
inhibitory effect on PP1 activity. We then utilized a modified
histone peptide array to test this possibility, finding that PNUTS,
but not SNIP1, directly recognized acetylated histones, including
H4K20ac, H3K18ac, H3K9ac, H3K27ac, and H4K16ac (Fig-
ure 6C), which was confirmed by histone peptide pull-down
experiments (Figure 6D). A previous study indicated that a mini-
mum region from 445–450 aa of PNUTS is required to inhibit the
phosphatase activity of PP1 (Kim et al., 2003).We then examined
if acetylated histone could also recognize this region, finding that
deletion of aa 443–455 of PNUTS abolished its interaction with
acetylated histone H3 (Figure 6E), suggesting that the inhibitory
role of PNUTS, mediated by motif aa 443–455, is attenuated in
the presence of acetylated histone, leading to activation of
PP1 enzymatic activity. Consistently, acetylated, but not methyl-
ated, histone peptides specifically rescued PP1 activity from
PNUTS inhibition (Figure 6F).
PP1 has been reported to dephosphorylate the carboxyl termi-
nal domain (CTD domain) of RNA polymerase II at Ser5, which is
accumulated at promoter regions of target genes (Komarnitsky
et al., 2000; Washington et al., 2002). A recent study showed
that depletion of PNUTS in Drosophila results in global
hyperphosphorylation of RNA Pol II Ser5, leading to global tran-Figure 4. BCAR4 Is Required for CCL21-Triggered, Phospho-GLI2-Me
(A–C) ChIP quantitative real-time PCR detection of GLI2 (A), phospho-GLI2 (B), o
promoters of selected GLI2 target genes in MDA-MB-231 cells treated with CCL
(D) qRT-PCR detection of GLI2 target genes expression in MDA-MB-231 cells tr
(E–G) Cell migration assays in MDA-MB-231 cells transfected with indicated siR
(H) Matrigel cell invasion assay in cells transfected with indicated siRNAs. Left: r
(I and J) Matrigel cell invasion assay (I) or qRT-PCR detection of GLI2 target gen
followed by CCL21 treatment.
Error bars, SEM of three independent experiments (*p < 0.05, **p < 0.01, and ***
Cscription pause and development defect (Ciurciu et al., 2013).
Therefore, we tested if PNUTS/PP1 regulates phosphorylation
of RNA Pol II Ser5, finding that knockdown of PNUTS led to
the hyperphosphorylation of RNA Pol II Ser5 (Figures S6E and
S6F). We then investigated the functional roles of PNUTS-acet-
ylated histone interaction in regulating the status of RNA Pol II
Ser5 phosphorylation in the presence of a p300 inhibitor,
C646, which eliminated the histone acetylation as represented
by H3K18ac (Figures 6G, S6G, and S6H). Our data indicate
that CCL21-triggered recruitment of PNUTS and PP1 to the pro-
moters of GLI2 target genes was not affected by p300 inhibitor
(Figures 6G, S6G, and S6H) and that the levels of Pol II Ser5
phosphorylation on these promoters were decreased upon
CCL21 treatment (Figures 6G, S6G, and S6H). However, the
CCL21-induced hypophosphorylation of RNA Pol II Ser5 was
abolished in the presence of the p300 inhibitor (Figures 6G,
S6G, and S6H), suggesting that histone acetylation-dependent
PP1 activity modulates RNA Pol II Ser5 phosphorylation levels
at gene promoter regions. Taken together, the data demonstrate
the important roles of BCAR4, through its interaction with SNIP1
and PNUTS, in linking signal-induced acetylation of histone
to general transcription machinery during the activation of the
GLI2 target genes in breast cancer cells.
BCAR4 as a Potential Therapeutic Target for Breast
Cancer Metastasis
To further confirm the functional connection between BCAR4
and breast cancer metastasis, we performed functional rescue
experiments in which we depleted BCAR4 by LNA, followed by
overexpression in MDA-MB-231 cells of either LNA-resistant
full-length BCAR4 or truncated mutants defective for SNIP1 or
PNUTS binding (see Figures 2F–2H and S7A). In cell motility as-
says, knockdown of BCAR4 reduced migration and invasion of
MDA-MB-231 cells, which could be rescued by reintroduction
of full-length, but neither D212–D311 nor D968–D1087 truncated
form of BCAR4 (Figures S7B and S7C), even though the expres-
sion of full-length BCAR4 and the truncated forms were equal
(Figure S7A), and cell proliferation was not altered (data not
shown). Knockdown of BCAR4 also curtailed the expression
of GLI2 target genes and reintroduction of full-length BCAR4,
but neither D212–D311 nor D968–D1087 truncated forms of
BCAR4were able to robustly rescue the induction of these genes
(Figures S7D and S7E). Consistently, knockdown of BCAR4
abolished CCL21-induced SNIP1 and PNUTS interaction, while
reintroduction of full-length BCAR4, but neither D212–D311 nor
D968–D1087 truncated forms of BCAR4, was able to robustly
rescue the interaction (Figure S7F). These data suggest that
BCAR4 exerts a quantitatively important role in GLI2-dependentdiated Gene Activation and Cell Migration
r ChIRP quantitative real-time PCR detection of BCAR4 (C) occupancy on the
21. RPLP0 served as a non-GLI2 target gene control (A and B).
ansfected with control or BCAR4 siRNA followed by CCL21 treatment.
NA (E and F) or treated with CCL21 neutralization antibody (G).
epresentative images; right: statistical analysis.
es (J) in MCF7 cells electroporated with indicated BCAR4 expression vectors
p < 0.001). See also Figure S4.
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Figure 5. Signal-Induced BCAR4-SNIP1 Interaction Attenuates the Inhibitory Effect of SNIP1 on p300 HAT Activity
(A and B) RIP quantitative real-time PCR detection of the indicated RNAs retrieved by Myc-specific antibody in MDA-MB-231 cells electroporated with indicated
vectors followed by CCL21 treatment.
(C) In vitro HAT activity assays of p300 in the presence of WT SNIP1, full-length (FL) BCAR4, and their corresponding mutants as indicated.
(D) In vitro HAT activity assays of p300 in the presence of WT SNIP1 and its corresponding mutants as indicated.
(E) IB detection of the interaction between SNIP1 (aa 97–274) and p300 (aa 1198–1806) WT or truncations.
(F) In vitro HAT activity assays of p300 in the presence of SNIP1 aa 97–274 and BCAR4 sense or antisense RNAs.
(G) ChIP quantitative real-time PCR detection of acetylated histone marks occupancy on the promoters of selected GLI2 target genes in MDA-MB-231 cells
treated with CCL21.
(H) ChIP quantitative real-time PCR detection of phospho-GLI2, p300, and H3K18Ac occupancy on PTCH1 promoter in MDA-MB-231 cells transfected with
indicated siRNAs followed by CCL21 treatment.
Error bars, SEM of three independent experiments (*p < 0.05 and **p < 0.01). See also Figure S5.
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Figure 6. Recognition of BCAR4-Dependent Histone Acetylation by PNUTS Attenuates Its Inhibitory Effect on PP1 Activity
(A) RIP quantitative real-time PCR detection of the indicated RNAs retrieved by Myc-specific antibody in MDA-MB-231 cells transfected with indicated vectors
followed by CCL21 treatment.
(B) In vitro phosphatase activity assays of PP1A in the presence of indicated proteins or nucleosome.
(C) MODified Histone Peptide Array detection of histone marks recognition by SNIP1 or PNUTS. Top: representative images; bottom: binding specificity.
(D and E) IB detection of PNUTS retrieved by biotinylated histone peptides as indicated from lysate ofMDA-MB-231 cells (D) orMDA-MB-231 cells electroporated
with indicated vectors (E).
(legend continued on next page)
Cell 159, 1110–1125, November 20, 2014 ª2014 Elsevier Inc. 1121
target gene activation and cell migration/invasion via its direct in-
teractions with SNIP1 and PNUTS.
Next, we recapitulated the contribution of BCAR4 to breast
cancer metastasis in vivo using highly metastatic MDA-MB-
231 LM2 cells harboring shRNA-targeting BCAR4, which
showed reduced migration and invasion (see Figures S4B–
S4D). Bioluminescent imaging (BLI) measurements revealed
that mammary gland fat-pad injection ofMDA-MB-231 LM2 cells
harboring control shRNA resulted in lung metastases in NOD/
SCID mice, whereas lung metastasis was significantly reduced
in two individual groups of mice injected with cells harboring
BCAR4 shRNA (Figure 7A), which was confirmed by quantifica-
tion of lung metastasis nodules (with an average of 11.2 per
mouse in control group and an average of two visiblemetastases
permouse inBCAR4 knockdown groups) and histological exam-
ination (Figures 7B and 7C).BCAR4 knockdown had no effect on
primary tumor size, tumor cell proliferation, or apoptosis (Figures
S7G and S7H), indicating that the metastasis suppression
phenotype is not secondary to impaired proliferation or
apoptosis. However, CD31, a marker for angiogenesis, was
significantly downregulated byBCAR4 knockdown (Figure S7H),
suggesting that reduced lung metastasis burden is due to
defective angiogenesis. Independently, the mice with tail-vein
injection of BCAR4 knockdown cells rarely developed lung
metastases (Figures 7D–7F). Immunohistochemical analyses
confirmed efficient inhibition of metastasis (Figure S7I). These
data suggest thatBCAR4 contribute to breast cancermetastasis
and silencing of BCAR4 inhibits lung metastasis in transplant-
able mouse models.
To evaluate the potential therapeutic potential of BCAR4,
we synthesized LNAs targeting BCAR4. Transfection of LNAs
against BCAR4 into MDA-MB-231 cells exhibited strong knock-
down efficiency (see Figure S1I) and dramatically affected cell
migration and invasion (data not shown). Next, we examined
the therapeutic efficacy of systemically administered in vivo-opti-
mized LNAs in breast cancermetastasis prevention. Of note, two
individual LNA treatments significantly reduced lung metastases
(Figures 7G and 7H) without notable weight loss (Figure S7J).
Importantly, therapeutic LNA-mediated BCAR4 targeting was
confirmed by qRT-PCR analysis of lung metastatic nodules (Fig-
ure 7I). Taken together, our findings reveal a BCAR4-dependent
regulatory network that converges onto a noncanonical hedge-
hog signaling pathway mediated by phospho-GLI2 to control
metastatic initiation and progression in breast cancer.
DISCUSSION
Effective treatment options for breast cancer metastasis, espe-
cially for TNBC is not well established. lncRNA-based mecha-
nisms in breast cancer may represent the crucial nodal points
for therapeutic intervention. Our studies have revealed that the
lncRNA BCAR4 is highly upregulated in advanced breast cancer
patients and contributes to breast cancer metastasis mediated(F) In vitro phosphatase activity assays of PP1A in the presence of PNUTS and m
(G) ChIP quantitative real-time PCR detection of H3K18Ac, PNUTS, Pol II Ser5 (n
MDA-MB-231 cells pretreated with C646 followed by CCL21 treatment.
Error bars, SEM of three independent experiments (*p < 0.05 and **p < 0.01). Se
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factors with extended regulatory consequences, licensing the
activation of a noncanonical hedgehog/GLI2 transcriptional pro-
gram that promotes cell migration (Figure 7J). In a variety of can-
cer types, including prostate, breast, ovarian, and pancreatic
cancers, hedgehog signaling pathways, which are critical for tu-
mor progression and invasion, are aberrantly activated. We are
tempted to speculate that other lncRNAs in these cancer types
recognize covalent modifications of GLI2 or other proteins and
exert an analogous function to promote the aberrant cancer
signaling pathways, which confers cancer cells the invasiveness
and metastatic propensity.
Although our data reveal that BCAR4 exerts a quantitatively
important role in chemokine-dependent Hedgehog target gene
activation in breast cancer cells, the full mechanisms by which
it functions in development remain incompletely defined.
BCAR4 is also highly expressed in human oocyte and placenta
(Godinho et al., 2011), suggesting its potential roles in develop-
ment. Interestingly, hedgehog ligands are expressed in a tis-
sue-specific manner, e.g., desert hedgehog (Dhh) expression
is specific to sertoli cells of the testes and granulosa cells of
ovaries (Varjosalo and Taipale, 2008). These observations indi-
cate that BCAR4 is also critical for GLI-mediated gene expres-
sion during development.
The BCAR4 upregulation in breast cancer could be the result
of the dysregulation of estrogen receptor (ER). Previous studies
have shown that BCAR4 is upregulated in response to tamoxifen
treatment of breast cancer cells (Godinho et al., 2011); thus, up-
regulation of BCAR4 could be the result of ER downregulation,
as seen in TNBC. It is also possible that BCAR4 expression is
regulated at the transcriptional level by certain aberrant onco-
genic signaling pathways in breast cancer cells or by gene ampli-
fication at the genomic level. Thus, BCAR4 expression may
require further investigation.
The targeting of lncRNAs with LNAs in breast cancer has not
gained much momentum due to the lack of identification of crit-
ical breast cancer-relevant lncRNAs and rigorous investigation
of the potential anticancer effects of the modulation of lncRNAs
in vivo. The important prognostic capacity of BCAR4 and the
robust metastasis suppression by therapeutically delivered
LNA targeting BCAR4 documented in our study encourage
future development of lncRNA-based cancer therapies for pa-
tients at high risk for metastasis, an outcome currently lacking
effective chemotherapeutic options.
EXPERIMENTAL PROCEDURES
lncRNA Array Version 3.0
Total RNA was extracted from two pairs of fresh frozen infiltrating ductal car-
cinomas of the breast and their adjacent normal breast tissues. RNA samples
were subjected to human genome-wide lncRNAmicroarray (v. 3.0) analyses at
ArrayStar. lncRNA array data have been deposited in the Gene Expression
Omnibus database under accession GSE60689. Details are included in the
Extended Experimental Procedures.odified histones H3 as indicated.
ormalized by Pol II occupancy), and PP1A occupancy on PTCH1 promoter in
e also Figure S6.
Figure 7. The Potential Therapeutic Role of BCAR4 in Breast Cancer Metastasis
(A–C) Representative bioluminescent (BLI) images (A), metastatic nodules numbers in the lungs (B), or isolated lung bright-field imaging (top) and hematoxylin and
eosin staining (middle and bottom) (C) of mice with fat-pad injection of MDA-MB-231 LM2 cells harboring indicated shRNA. Data are means ± SEM (n = 5).
(D–F) Representative BLI images (D), lung colonization (E), and metastatic nodules numbers in the lungs (F) of mice with tail-vein injection of MDA-MB-231 LM2
cells harboring indicated shRNA. Data are means ± SEM (n = 5).
(legend continued on next page)
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Tissue Specimens
Fresh frozen breast carcinomas and their adjacent normal tissues were pur-
chased from Asterand. Breast cancer tissue microarrays were purchased
from Biomax and U.S. BioLab and were grouped into two sets: training
set (BC081120, BR1505a, and BR487 from Biomax) and validation set
(Bre170Sur-01 from U.S. Biolab). All clinicopathological features of tissue
specimens are listed in Table S2. The protocol was approved by the Institu-
tional Review Board at the MD Anderson Cancer Center.
RNAScope Assay
The RNAScope probe targeting BCAR4 was designed and synthesized by
Advanced Cell Diagnostics and detection of BCAR4 expression was per-
formed using the RNAscope 2.0 High Definition (HD)—BROWN Assay in
accordance with the manufacturer’s instructions (Advanced Cell Diagnostics).
The images were acquired with Zeiss Axioskop2 Plus Microscope.
RNA Pull-Down and Mass Spectrometry Analysis
Biotin-labeled BCAR4 RNAs were in vitro transcribed with the Biotin RNA La-
beling Mix (Roche) and T7 or SP6 RNA polymerase (Ambion) and purified by
RNA Clean & Concentrator-5 (Zymo Research). The cell lysates were freshly
prepared using ProteaPrep Zwitterionic Cell Lysis Kit, Mass Spec Grade
(Protea) with Anti-RNase, Protease/Phosphatase Inhibitor Cocktail, Panobi-
nostat, and Methylstat, supplemented in the lysis buffer. The BcMag Mono-
mer Avidin Magnetic Beads (Bioclone) were first prepared in accordance
with manufacturer’s instructions and then immediately subjected to RNA
(20 mg) capture in RNA capture buffer (20 mM Tris-HCl [pH 7.5], 1 M NaCl,
and 1 mM EDTA) for 30 min at room temperature with agitation. The RNA-
captured beads were washed once with NT2 buffer (50 mM Tris-HCl [pH
7.4], 150 mM NaCl, 1 mM MgCl2, and 0.05% NP-40) and incubated with
30 mg cell lysates diluted in NT2 buffer supplemented with 50 U/ml RNase
OUT, 50 U/ml SuperasedIN, 2 mM dithiothreitol, 30 mM EDTA, and Heparin
0.02 mg/ml for 2 hr at 4C with rotation. The RNA-binding protein complexes
were washed sequentially with NT2 buffer (twice), NT2 high-salt buffer
containing 500 mM NaCl (twice), NT2 high-salt buffer containing 1 M NaCl
(once), NT2-KSCN buffer containing 750 mM KSCN (twice), and PBS
(once) for 5 min at 4C and eluted by 2 mM D-biotin in PBS. The eluted pro-
tein complexes were denatured, reduced, alkylated, and digested with im-
mobilized trypsin (Promega) for MS analysis at MD Anderson Cancer Center
Proteomics Facility.
In Vivo Breast Cancer Metastasis Assays
All animal studies were performed with MD Anderson Cancer Center’s Institu-
tional Animal Care and Use Committee (IACUC) approval. In vivo spontaneous
and experimental breast cancer metastasis assays were performed as
described (Chen et al., 2012; Minn et al., 2005). For animal study with LNA in-
jection, mice were intravenously injected with in vivo -grade LNAs (Exiqon) in
PBS (15 mg/kg) twice a week for three weeks after MDA-MB-231 LM2 cells in-
jection. The tumor growth and lung metastasis were monitored by Xenogen
IVIS 100 Imaging System.
Data Analysis and Statistics
Relative quantities of gene expression level were normalized to B2M. The rela-
tive quantities of ChIP and ChIRP samples were normalized by individual in-
puts, respectively. Results are reported as mean ± SEM of three independent
experiments. Comparisons were performed using two-tailed paired Student’s
t test. *p < 0.05, **p < 0.01, and ***p < 0.001. Fisher’s exact test was used for
statistical analyses of the correlation between eachmarker and clinical param-
eters. For survival analysis, the expression of BCAR4 was treated as a binary
variable, divided into ‘‘high’’ and ‘‘low’’ BCAR4 expression. Kaplan-Meier sur-(G and H) Representative BLI images (G) and lung colonization (H) of mice at day
LNA treatment. Data are means ± SEM (n = 3).
(I) qRT-PCR detection of BCAR4 expression in sorted GFP-positive MDA-MB-2
treated with LNA at day 30 (n = 3).
(J) A model for cooperative epigenetic regulation downstream of chemokine sign
See also Figure S7.
1124 Cell 159, 1110–1125, November 20, 2014 ª2014 Elsevier Inc.vival curves were compared by the Gehan-Breslow Test in Graphpad Prism
(GraphPad Software).
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